Investor Relations

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes antibodies, antibody-drug conjugates and other protein-based therapeutics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Therapeutics Announces Upcoming Data Presentations
HAMPTON, N.J. , Oct. 02, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that multiple Company drug development programs will be the subject of presentations at upcoming medical and scientific conferences. Society for Immunotherapy of Cancer ( SITC ) 34th Annual
Toggle Summary Celldex Therapeutics to Present at the Cantor Global Healthcare Conference
HAMPTON, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci , Co-founder, President and Chief Executive Officer, and Tibor Keler , PhD, Cofounder, Executive Vice President and Chief Scientific Officer, will present a corporate

Upcoming Events

There are currently no events to display.

Featured Financial Reports

Show all

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline